166 related articles for article (PubMed ID: 30467045)
1. Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.
Dall'Olio FG; Sperandi F; Rihawi K; Gargiulo M; Melotti B; Brocchi S; Gelsomino F; Ardizzoni A
J Thorac Oncol; 2018 Dec; 13(12):e247-e248. PubMed ID: 30467045
[No Abstract] [Full Text] [Related]
2. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.
Keung YK; Hu EH
J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627
[TBL] [Abstract][Full Text] [Related]
3. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
[No Abstract] [Full Text] [Related]
4. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
5. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
6. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
[No Abstract] [Full Text] [Related]
7. Arterial thrombosis and anti-PD-1 blockade.
Boutros C; Scoazec JY; Mateus C; Routier E; Roy S; Robert C
Eur J Cancer; 2018 Mar; 91():164-166. PubMed ID: 29289455
[No Abstract] [Full Text] [Related]
8. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
[No Abstract] [Full Text] [Related]
9. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A
Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027
[No Abstract] [Full Text] [Related]
10. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
[No Abstract] [Full Text] [Related]
11. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
[No Abstract] [Full Text] [Related]
12. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
13. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
Lee SY; Kim MH; Jang M; Park Y; Cho BC
Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
[No Abstract] [Full Text] [Related]
14. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series.
Tomelleri A; Campochiaro C; De Luca G; Cavalli G; Dagna L
Eur J Intern Med; 2018 Nov; 57():e11-e12. PubMed ID: 30076088
[No Abstract] [Full Text] [Related]
15. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
[No Abstract] [Full Text] [Related]
16. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
[No Abstract] [Full Text] [Related]
17. Nivolumab-induced Pancreatitis: An Immune-related Adverse Event.
Saito H; Ono K
Radiology; 2019 Dec; 293(3):521. PubMed ID: 31617817
[No Abstract] [Full Text] [Related]
18. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection.
Lee BT; Horwich BH; Chopra S; Ahearn A; Han HH
Liver Transpl; 2019 Dec; 25(12):1845-1848. PubMed ID: 31408574
[No Abstract] [Full Text] [Related]
19. A Cautionary Note: "Real-World" Toxicity of Checkpoint Inhibitors.
Markman M
Oncology; 2018; 94(5):257-258. PubMed ID: 29444519
[No Abstract] [Full Text] [Related]
20. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
[No Abstract] [Full Text] [Related]
[Next] [New Search]
